CORDIS · 101091554 · HORIZON
HYPER An electrochemically produced oxidiser for modular, onsite generation of HYdrogen PERoxide
Coordinator: SINTEF AS (NO)
Hydrogen peroxide (H2O2) has many industrial applications, e.g., as chemical reagent and bleaching agent for textiles and wood pulp. The established production route of H2O2 is the autooxidation/ anthraquinone process, which uses natural gas as both feedstock and energy source.The main objective of HYPER is the demonstration, in industrially relevant environments, of a scalable, modular electrochemical process for H2O2 production with improved efficiency compared to the state-of-art. It will bridge this production with downstream integration into diverse value chains, pulp and paper, textiles…
About Horizon Europe (2021–2027)
Horizon Europe is the EU's current research and innovation programme, covering 2021 to 2027 with a budget of roughly €95.5 billion. Its three pillars are Excellent Science (frontier research and mobility), Global Challenges and European Industrial Competitiveness (mission-driven collaborative projects in health, climate, digital, security and food) and Innovative Europe (the EIC and EIT). It also funds five EU Missions targeting cancer, climate adaptation, smart cities, oceans and soils.
EU contribution: €7.3M awarded to the consortium. The project runs over approximately 4 years from 2023-01-01 to 2026-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from NO
see all →- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · H2020 · €100.0M
- CHIKVAX_CHIM — Late-stage clinical development of Chikungunya vaccines in endemic countries (CHIKV) and Controlled Human Infection Models for SARS-CoV2 and other beta coronaviruses (CHIM).101126531 · HORIZON · €70.0M
- ECRC — Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola857934 · H2020 · €36.0M
- FILOVAX — Development of Broadly Protective Filovirus Vaccines101167138 · HORIZON · €35.0M
- RIFTVAX — Clinical development of Rift Valley fever vaccines in endemic regions101081290 · HORIZON · €35.0M
- REFHYNE II — Clean Refinery Hydrogen for Europe II101036970 · H2020 · €32.4M
Other HORIZON projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon Europe through a joint programme of the members of the EUROfusion consortium101052200 · DE · €549.4M
- EITUM-BP26-28 — EIT Urban Mobility Business Plan 2026-2028101269525 · ES · €206.9M
- PARC — Partnership for the Assessment of Risks from Chemicals101057014 · FR · €200.0M
- EIT RM BP23-25 — EIT RawMatrials Business Plan 2023-2025101113034 · DE · €155.5M
- SGA1-HE — COST: Europe's most empowering research programme Strengthening science and innovation through research networking101052416 · BE · €153.0M
- EIT HEI — EIT Higher Education Initiative - Scaling Europe’s Innovation Ecosystems101270329 · DE · €130.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon Europe (2021–2027) programme, under the HORIZON-RIA funding scheme.
- What is the EU contribution?
- The European Commission contributes €7.3M toward a total project budget of €7.3M.
- Which EU programme funds it?
- The project is funded under Horizon Europe (2021–2027), call HORIZON-CL4-2022-TWIN-TRANSITION-01.
- Who coordinates the project?
- The project is coordinated by SINTEF AS (NO).
- What is the project timeline?
- The project runs from 2023-01-01 to 2026-12-31 — approximately 4 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 101091554.